Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Inclusion Criteria: * Solid tumors or lymphoid malignancies refractory to standard therapy * measurable disease * recovery to Grade \< 1 toxicity due to prior adverse event or chemotherapy * no chemotherapy within 4 weeks of entering study * Age \> 18 years * Karnofsy \>= 60% * Life expectancy \> 3 months * normal or adequate organ and marrow function Exclusion Criteria: * receiving other investigational agents * brain metastases * uncontrolled medical illness * HIV+ receiving combination antiretroviral therapy * significant GI disease